Clinical trials: Neoplasm Circulating Cells
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Prostatic Neoplasms
Measurement of Circulating Tumor Cells in Prostate Cancer
Can tumor cells and tumor DNA be sampled from blood samples from prostate cancer patients? Is it possible to understand the causal relationship between the occurrence of the tumor cells and the tumor DNA in the blood by reviewing…
- Trial name
- ICELLATEPC (NCT04101305)
- Testing
- IsoPic
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Sormland County Council, Sweden
Carcinoma, Hepatocellular, Neoplasm Circulating Cells
Circulating Tumor Cells for Hepatocellular Carcinoma
To explore the clinical value of circulating tumor cells (CTCs) measurement for Hepatocellular carcinoma (HCC) patients.
- Trial name
- CTCs for HCC (NCT01930383)
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Lung Cancer
Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection
Validation of biomolecular markers in the circulation and radiomic features are the focus of this project.The aim is to assess the role of molecular and cellular biomarkers (exosomes antigens, Circulating tumor cells - CTCs…
- Trial name
- SMAC-2 (NCT04315753)
- Testing
- LDCT (Low Dose CT)
- Where
- Italy
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
NSCLC
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
The second generation of high-throughput gene sequencing (NGS) is an important means of detecting the tumor DNA and circulating tumor DNA (ctDNA), which can detect trace ctDNA from smaller plasma samples.
- Trial name
- NCT03465241
- Testing
- the ctDNA dynamic monitoring
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Leptomeningeal Metastasis
Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
This study will prospectively enroll 36 evaluable subjects with breast cancer who are undergoing workup for clinical suspicion of leptomeningeal metastasis (LM).
- Trial name
- NCT02948751
- Testing
- OncoCEE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Columbia University
Cancer, Breast Cancer
Analysis of Circulating Tumor Markers in Blood
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency…
- Conditions
- Cancer, Breast Cancer, Sarcoma, Lung Cancers
- Trial name
- ALCINA2 (NCT04025541)
- Testing
- Blood sampling, Blood sampling C3, Blood sampling C4/7/10/13
- Where
- 2 sites in France
- Volunteers
- 992 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Non-small Cell Lung Cancer
Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Trial name
- NCT03700437
- Testing
- Fasting-Mimicking Diet
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Paraneoplastic Neurological Syndromes
Liquid Biopsy in Paraneoplastic Neurological Syndromes
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined…
- Trial name
- LiB-PNS (NCT07491328)
- Testing
- CTC & ctDNA analysis
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Tobacco, Cancer
Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells
Tobacco smoke is the most common source of exposure to carcinogens in humans. Indeed, the smoke contains about 1010 particles per ml and 4800 chemical compounds, at least 66 are carcinogenic.
- Conditions
- Tobacco, Cancer, Screening, Psychology
- Trial name
- DETeCTOR (NCT02849041)
- Testing
- medical imaging, Identification of Circulating Tumor Cells, Psychological Questionnaires
- Where
- France
- Volunteers
- 176 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Neuroendocrine Neoplasms
Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE Consortium
The CollectNET 2.0 by BE-FORCE is a prospective, multicentric, interventional study in which liquid biopsies will be collected from neuroendocrine neoplasms (NEN) patients to create an extensive biobank that will be used for…
- Trial name
- BE-FORCE (NCT06541080)
- Testing
- Shallow Whole Genome Sequencing (sWGS)-GIPXplore, methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay
- Where
- 8 sites in Belgium
- Volunteers
- 550 people
- Sponsor
- University Hospital, Antwerp
Bladder Cancer
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
The investigators hypothesize that circulating tumor cells (CTC) will be observed in patients with muscle-invasive or metastatic bladder cancer and that CTC will become undetectable, at least transiently, in a fraction of…
- Trial name
- NCT00829920
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
The purpose of this study is to identify tumor cells in the bloodstream (Circulating Tumor Cells, CTC's) from patient's with locally advanced or metastatic (stage IV) breast cancer.
- Conditions
- Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer, Stage III-IV Breast Cancer or Inflammatory
- Trial name
- NCT01048918
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer Metastatic
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The aim of the study is to assess the clinical utility of 18F-fluoro-deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) and Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and…
- Trial name
- NCT02814968
- Testing
- Enzalutamide, 18-FDG PET/CT, Whole body MRI
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- The European Uro-Oncology Group
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cervical Dysplasia, Uterine, Vaginal Dysplasia
Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests
Uterine cervical dysplasia and other female genital dysplasia continue to be significant health problems despite Cervical Screening Programs and HPV vaccinations being available.
- Conditions
- Cervical Dysplasia, Uterine, Vaginal Dysplasia, Vulvar Dysplasia
- Trial name
- TTMV HPV DNA (NCT05536843)
- Volunteers
- 500 people
- Sponsor
- University of Mississippi Medical Center
Carcinoma, Non-small-cell Lung Cancer
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02696525
- Where
- 3 sites in China
- Volunteers
- 145 people
- Sponsor
- Peking University People's Hospital
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with non-squamous non-small cell lung cancer which has spread to other places in the body.
- Trial name
- NCT02955758
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Joel Neal
Non-small Cell Lung Cancer
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
- Trial name
- NCT06198868
- Testing
- Operable
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Cancer Institute & Hospital